Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Mecbotamab Vedotin |
Trade Name | |
Synonyms | BA3011|CAB-AXL-ADC|BA-3011|BA 3011 |
Drug Descriptions |
Mecbotamab Vedotin is an antibody-drug conjugate comprising a reversible Axl antibody conjugated to monomethyl auristatin E (MMAE), which delivers the cytotoxic agent to Axl-expressing tumor cells, potentially inducing cytotoxicity and tumor growth inhibition (Cancer Res 2018;78(13 Suppl):Abstract nr 827; Journal of Clinical Oncology 2018 36:15_suppl, TPS12126). |
DrugClasses | AXL Antibody 5 |
CAS Registry Number | 2460400-64-8 |
NCIT ID | C156141 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Durvalumab + Mecbotamab Vedotin | Durvalumab Mecbotamab Vedotin | 0 | 1 |
Mecbotamab Vedotin | Mecbotamab Vedotin | 0 | 2 |
Mecbotamab Vedotin + unspecified PD-1 antibody | Mecbotamab Vedotin unspecified PD-1 antibody | 0 | 1 |